CERO THERAPEUTICS HOLDINGS, INC. Quarterly Net Income (Loss) Attributable to Parent in USD from Q2 2021 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Cero Therapeutics Holdings, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2021 to Q3 2024.
  • Cero Therapeutics Holdings, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$4.23M, a 213% decline year-over-year.
  • Cero Therapeutics Holdings, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$8.98M, a 46.1% decline year-over-year.
  • Cero Therapeutics Holdings, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$2.54M, a 280% decline from 2022.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 -$4.23M -$2.88M -213% Sep 30, 2024 10-Q/A 2024-11-20
Q2 2024 -$2.45M -$356K -17% Jun 30, 2024 10-Q 2024-08-14
Q1 2024 -$1.73M +$711K +29.2% Mar 31, 2024 10-Q 2024-05-17
Q4 2023 -$572K -$310K -118% Feb 13, 2024 10-Q/A 2024-11-20
Q3 2023 -$1.35M -$1.43M -1697% Sep 30, 2023 10-Q/A 2024-11-20
Q2 2023 -$2.09M -$1.98M -1776% Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$2.44M -$2.06M -545% Mar 31, 2023 10-Q 2024-05-17
Q4 2022 -$263K Dec 31, 2022 10-K 2024-04-02
Q3 2022 $84.5K +$84.5K Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$112K +$888K +88.8% Jun 30, 2022 10-Q 2023-11-09
Q1 2022 -$378K Mar 31, 2022 10-Q 2023-11-09
Q3 2021 $0 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$1M Jun 30, 2021 10-Q 2022-11-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.